Responses to PD-1 Blockade Approach 90% in Rare Melanoma

(MedPage Today) -- ORLANDO -- Exceedingly high response rates were seen with pembrolizumab (Keytruda) in patients with unresectable metastatic desmoplastic melanoma, according to results from the SWOG S1512 phase II trial presented here. Among...
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news